Are Antiphospholipid Antibodies a Surrogate Risk Factor for Thrombosis in Sepsis?

Jecko Thachil; Emmanuel J. Favaloro; Giuseppe Lippi

doi:10.1055/s-0043-1771268

Seminars in Thrombosis and Hemostasis, Table of Contents

Semin Thromb Hemost 2024; 50(02): 284-287
DOI: 10.1055/s-0043-1771268

Commentary

Are Antiphospholipid Antibodies a Surrogate Risk Factor for Thrombosis in Sepsis?

Jecko Thachil

¹Department of Haematology, Manchester University Hospitals, Manchester, United Kingdom

,

Emmanuel J. Favaloro

²Department of Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, NSW, Australia

³Sydney Centres for Thrombosis and Haemostasis, Westmead, NSW, Australia

⁴Faculty of Science and Health, Charles Sturt University, Wagga Wagga, NSW, Australia

⁵School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, Westmead Hospital, Westmead, New South Wales, Australia

,

Giuseppe Lippi

⁶Section of Clinical Biochemistry, University of Verona, Verona, Italy

› Author Affiliations

Abstract

Antiphospholipid syndrome (APS) is a hypercoagulable state caused by antiphospholipid antibodies (aPL). APS clinically manifests with arterial or venous or microvascular thrombi and/or pregnancy complications. It is well-known that the development of aPL can be a transient phenomenon and thus the current diagnostic criterion for APS requires repeat laboratory testing several weeks apart before a definitive diagnosis is made. However, transient presence of aPL may also be pathogenic. In this article, we attempt to give historical and clinical evidence for the importance of these antibodies, even when transient, and call for further research into mechanisms by which these antibodies may promote thrombosis and pregnancy morbidities.

Keywords

antiphospholipid - lupus anticoagulant - pregnancy - sepsis - thromboembolism

Full Text

References

References
1 Maneta E, Aivalioti E, Tual-Chalot S. et al. Endothelial dysfunction and immunothrombosis in sepsis. Front Immunol 2023; 14: 1144229
2 Knight JS, Kanthi Y. Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome. Semin Immunopathol 2022; 44 (03) 347-362
3 Sciascia S, Radin M, Bazzan M. et al. Antiphospholipid antibodies and infection: non nova sed nove . Front Immunol 2021; 12: 687534
4 Uthman IW, Gharavi AE. Viral infections and antiphospholipid antibodies. Semin Arthritis Rheum 2002; 31 (04) 256-263
5 Devreese KMJ, de Groot PG, de Laat B. et al. Guidance from the Scientific and Standardization Committee for lupus anticoagulant/antiphospholipid antibodies of the International Society on Thrombosis and Haemostasis: update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18 (11) 2828-2839
6 Devreese KMJ, Ortel TL, Pengo V, de Laat B. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibodies. Laboratory criteria for antiphospholipid syndrome: communication from the SSC of the ISTH. J Thromb Haemost 2018; 16 (04) 809-813
7 Jayakody Arachchillage D, Greaves M. The chequered history of the antiphospholipid syndrome. Br J Haematol 2014; 165 (05) 609-617
8 Asherson R, Cervera R, Piette JC. et al. The Antiphospholipid Syndrome: History, Definition, Classification and Differential Diagnosis in the Antiphospholipid Syndrome. Boca Raton, Florida, United States: CRC Press; 1996: 3-12
9 Pagborn MC. A new serologically active phospholipid from beef heart. Proc Soc Exp Biol Med 1941; 44: 484-486
10 Harris A, Riedel LM, Riedel LM. A microflocculation test for syphilis using cardiolipin antigen; preliminary report. J Vener Dis Inf 1946; 27 (07) 169-174
11 Moore JE, Mohr CF. Biologically false positive serologic tests for syphilis; type, incidence, and cause. J Am Med Assoc 1952; 150 (05) 467-473
12 Lubinski HH. Interpretation and significance of false positive serological reactions for syphilis. Can Med Assoc J 1947; 57: 33-35
13 Asherson RA, Cervera R. Antiphospholipid antibodies and infections. Ann Rheum Dis 2003; 62 (05) 388-393
14 Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res 2012; 129 (03) 290-295
15 Rodríguez-Pintó I, Moitinho M, Santacreu I. et al; CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies). Catastrophic antiphospholipid syndrome (CAPS): descriptive analysis of 500 patients from the International CAPS Registry. Autoimmun Rev 2016; 15 (12) 1120-1124
16 Fischetti F, Durigutto P, Pellis V. et al. Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor. Blood 2005; 106 (07) 2340-2346
17 Jankowski M, Vreys I, Wittevrongel C. et al. Thrombogenicity of β 2-glycoprotein I-dependent antiphospholipid antibodies in a photochemically induced thrombosis model in the hamster. Blood 2003; 101 (01) 157-162
18 Meroni PL, Borghi MO, Raschi E, Tedesco F. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7 (06) 330-339
19 Giannakopoulos B, Krilis SA. The pathogenesis of the antiphospholipid syndrome. N Engl J Med 2013; 368 (11) 1033-1044
20 Bowles L, Platton S, Yartey N. et al. Lupus anticoagulant and abnormal coagulation tests in patients with COVID-19. N Engl J Med 2020; 383 (03) 288-290
21 Zhang Y, Xiao M, Zhang S. et al. Coagulopathy and antiphospholipid antibodies in patients with COVID-19. N Engl J Med 2020; 382 (17) e38
22 Helms J, Tacquard C, Severac F. et al; CRICS TRIGGERSEP Group (Clinical Research in Intensive Care and Sepsis Trial Group for Global Evaluation and Research in Sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 2020; 46 (06) 1089-1098
23 Foret T, Dufrost V, Salomon Du Mont L. et al. Systematic review of antiphospholipid antibodies in COVID-19 patients: culprits or bystanders?. Curr Rheumatol Rep 2021; 23 (08) 65
24 Constans M, Santiago R, Jimenez L. et al. Lupus anticoagulant is an independent risk factor for non-thrombotic in-hospital mortality in COVID-19 patients. Thromb Res 2021; 208: 99-105
25 Pineton de Chambrun M, Frere C, Miyara M. et al. High frequency of antiphospholipid antibodies in critically ill COVID-19 patients: a link with hypercoagulability?. J Intern Med 2021; 289 (03) 422-424
26 Siguret V, Voicu S, Neuwirth M. et al. Are antiphospholipid antibodies associated with thrombotic complications in critically ill COVID-19 patients?. Thromb Res 2020; 195: 74-76
27 Favaloro EJ, Henry BM, Lippi G. Is lupus anticoagulant a significant feature of COVID-19? A critical appraisal of the literature. Semin Thromb Hemost 2022; 48 (01) 55-71
28 Favaloro EJ, Henry BM, Lippi G. COVID-19 and antiphospholipid antibodies: time for a reality check?. Semin Thromb Hemost 2022; 48 (01) 72-92
29 Zuo Y, Estes SK, Ali RA. et al. Prothrombotic autoantibodies in serum from patients hospitalized with COVID-19. Sci Transl Med 2020; 12 (570) eabd3876
30 Hollerbach A, Müller-Calleja N, Pedrosa D. et al. Pathogenic lipid-binding antiphospholipid antibodies are associated with severity of COVID-19. J Thromb Haemost 2021; 19 (09) 2335-2347
31 Minassian C, Thomas SL, Williams DJ, Campbell O, Smeeth L. Acute maternal infection and risk of pre-eclampsia: a population-based case-control study. PLoS One 2013; 8 (09) e73047
32 Conde-Agudelo A, Villar J, Lindheimer M. Maternal infection and risk of preeclampsia: systematic review and metaanalysis. Am J Obstet Gynecol 2008; 198 (01) 7-22
33 Yan L, Jin Y, Hang H, Yan B. The association between urinary tract infection during pregnancy and preeclampsia: a meta-analysis. Medicine (Baltimore) 2018; 97 (36) e12192
34 De Carolis S, Botta A, Santucci S. et al. Predictors of pregnancy outcome in antiphospholipid syndrome: a review. Clin Rev Allergy Immunol 2010; 38 (2-3): 116-124
35 De Carolis S, Caruso A, Ferrazzani S, Carducci B, De Santis L, Mancuso S. Poor pregnancy outcome and anticardiolipin antibodies. Fetal Diagn Ther 1994; 9 (05) 296-299
36 Simchen MJ, Goldstein G, Lubetsky A, Strauss T, Schiff E, Kenet G. Factor v Leiden and antiphospholipid antibodies in either mothers or infants increase the risk for perinatal arterial ischemic stroke. Stroke 2009; 40 (01) 65-70
37 Herrera CA, Heuser CC, Branch DW. Stillbirth: the impact of antiphospholipid syndrome?. Lupus 2017; 26 (03) 237-239